MLR Maelor

RNS Number:8742D
Maelor PLC
01 June 2006





   Maelor and Plethora Solutions enter into a licensing agreement for micelle
                                 nanotechnology



June 1st 2006 - Maelor Pharmaceuticals PLC ("Maelor"; AIM:MLR), the specialist
critical care company, and Plethora Solutions Holdings PLC ("Plethora" or the "
Company", AIM : PLE), a UK-based speciality pharmaceutical company, are pleased
to announce that Maelor has granted Plethora a licence to Maelor's micelle
nanotechnology delivery system.

Under the terms of the agreement, Maelor will provide Plethora with a worldwide,
exclusive licence to Maelor's micelle nanotechnology, for application in
Plethora's PSD597 programme for the treatment of interstitial cystitis and
painful bladder syndrome (IC/PBS).

Plethora will be responsible for product development and the licence agreement
is based upon an upfront payment, development and sales milestones and royalties
to Maelor.

Micelle nanotechnology entraps drug compounds inside minute particles built up
from polymers. This formulation technique can potentially deliver effective
concentrations of drugs which would otherwise be insoluble. The micelles may
also protect the entrapped drug from hydrolysis by enzymes or protect the drug
from extreme pH environments and thus enable more drug to be delivered to its
site of action.

Plethora has already completed clinical pilot studies which indicated that its
proprietary treatment, PSD597, can result in symptomatic relief from IC/PBS.
Plethora recently announced that it had initiated a Phase II, double-blind,
placebo-controlled clinical study in up to 20 centres in the US and Canada, with
preliminary results anticipated towards the end of 2006. In this study, PSD597
is being delivered locally into the bladder in a procedure conducted in an
out-patient clinic. Following successful completion of this study, the micelle
technology will be incorporated into the next stage of development and may open
up the potential for patients to self administer treatments for interstitial
cystitis.

IC/PBS is a condition characterised by chronic pelvic pain and afflicts up to
two million women in the United States and Europe. The causes of IC/PBS are
unknown and the few available approved treatments fail to bring about immediate
and long-lasting symptomatic relief.



Tim Wright, Chief Executive Officer of Maelor, commented:

"As a specialist urology company with expertise in the clinical development of
an IC/PBS treatment, Plethora is ideally placed to develop an effective and
convenient micelle-based product for this debilitating condition and we are
pleased to build upon their proprietary position in this area by providing
access to our micelle nanotechnology."



Steven Powell, Chief Executive Officer of Plethora, commented:



"Maelor's micelle delivery technology is an ideal enhancement for this product,
potentially broadening the patient population for this much needed treatment
which has unique benefits for IC/PBS sufferer."



Enquiries:


Maelor plc
Tim Wright, CEO
Tel: 01978 810153


Financial Dynamics
Ben Atwell/John Gilbert
Tel: 020 7831 3113


Plethora Solutions                                          Tel : 0207 269 8630
Steven Powell


Buchanan Communications                                     Tel : 0207 466 5000
Isabel Podda



Notes to Editors:



About Maelor:

Maelor plc is a specialist critical care pharmaceuticals and devices company.
The company commercialises its critical care portfolio directly in the UK and
commercialises early stage technology and non-core products through effective
relationships with partners.  The Company is headquartered in the UK and is
listed on the London Stock Exchange (AIM:MLR) Further information is available
at www.maelor.plc.uk



About Plethora:

Plethora is focused on the development of products for the treatment of
urological disease. The Company has products in clinical development for the
treatment of overactive bladder, benign prostatic hyperplasia, stress urinary
incontinence, interstitial cystitis and premature ejaculation. In January 2006,
Plethora acquired Minneapolis (Mn) based Timm Medical Technologies Inc which
markets products for the treatment of erectile dysfunction (ED) to urology
clinics through a US-based speciality sales team. The Company is headquartered
in the UK and is listed on the London Stock Exchange (AIM:PLE) Further
information is available at www.plethorasolutions.co.uk






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRAKDKDFBKDOPN

Maelor (LSE:MLR)
Historical Stock Chart
From Nov 2024 to Dec 2024

Maelor (LSE:MLR)
Historical Stock Chart
From Dec 2023 to Dec 2024